In clinical practice, discontinuation or dose reduction of everolimus may be induced not only by grade 3 or 4 toxicities but also by prolonged grade 2 toxicities, such as stomatitis and/or cutaneous toxicity, which share some pathogenetic mechanisms. We assessed the correlation between either everolimus discontinuation or dose reduction induced by stomatitis-cutaneous toxicity events (SCTE) and clinical outcome of patients with metastatic renal-cell cancer (mRCC).
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus / Conteduca, Vincenza; Santoni, Matteo; Medri, Matelda; Scarpi, Emanuela; Burattini, Luciano; Lolli, Cristian; Rossi, Lorena; Savini, Agnese; Berardi, Rossana; Stanganelli, Ignazio; Cascinu, Stefano; De Giorgi, Ugo. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1938-0682. - 14:5(2016), pp. 426-431. [10.1016/j.clgc.2016.02.012]
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus
CASCINU, Stefano;
2016
Abstract
In clinical practice, discontinuation or dose reduction of everolimus may be induced not only by grade 3 or 4 toxicities but also by prolonged grade 2 toxicities, such as stomatitis and/or cutaneous toxicity, which share some pathogenetic mechanisms. We assessed the correlation between either everolimus discontinuation or dose reduction induced by stomatitis-cutaneous toxicity events (SCTE) and clinical outcome of patients with metastatic renal-cell cancer (mRCC).
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1558767316300404-main.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
236.86 kB
Formato
Adobe PDF
|
236.86 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
